Phase 2 Study of TLK286 Administered Weekly in Advanced Non-Small Cell Lung Cancer

Phase 2

Completed

• Conditions: Carcinoma, Non-small-cell Lung

• Registration Number: NCT00040638
• Lead Sponsor: Telik

Brief Summary

The purpose of this study is to determine the effectiveness of TLK286 in the treatment of advanced non-small cell lung cancer.

Detailed Description

Not available

Study Timeline

• Study Start: 2002-07
• Study First Submitted: 2002-07-02
• Study First Submitted QC: 2002-07-03
• Study First Posted: 2002-07-04
• Primary Completion: 2003-08
• Study Completion: 2003-08
• Status Verified: 2011-06
• Last Update Submitted: 2011-07-21
• Last Update Posted: 2011-07-25

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 40

Inclusion Criteria

• Histologic or cytologic diagnosis of non-small cell lung carcinoma
• Progressed while on or after treatment on platinum-based regimen
• Patients may not have had more than one prior cytotoxic chemotherapy regimen
• Stage IV or IIIB
• Age at least 18 years
• Adequate liver and kidney function
• Adequate bone marrow function

Exclusion Criteria

• Pregnancy or lactation
• Unstable medical conditions
• Chemotherapy, hormonal therapy, radiotherapy, radiopharmaceuticals or immunotherapy within 3 weeks of TLK286
• CNS metastasis unless controlled by treatment

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Trial Locations

Locations (3)

Arizona Cancer Center; 🇺🇸 Tucson, Arizona, United States

UCLA Medical Center; 🇺🇸 Los Angeles, California, United States

M.D. Anderson Cancer Center; 🇺🇸 Houston, Texas, United States